ERB 257

Drug Profile

ERB 257

Alternative Names: ERB-257

Latest Information Update: 10 Aug 2009

Price : $50

At a glance

  • Originator Wyeth
  • Class
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Sepsis

Most Recent Events

  • 06 May 2009 ERB 257 is discontinued following completion of phase I trials (US and Japan)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top